ALPHA Sitagliptin Add on to Metformin (0431-103)

Merck Sharp & Dohme LLC608 enrolled

Overview

Canadian physicians to experience in real life clinical practice the efficacy and tolerability of adding sitagliptin to their patients who have their glycemic levels inadequately controlled while on metformin

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

608

Conditions

Diabetes Mellitus

Interventions

sitagliptin phosphateDRUG

Sitagliptin 100 mg/day - tablet for 24 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patient Is Currently On Monotherapy With Metformin For At Least 10 Weeks Prior To Study Entry

Outcomes

Primary Outcomes

Change From Baseline in HbA1c at Week 24

HbA1c is measured as percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent

Time frame: Baseline and Week 24

Secondary Outcomes

Change From Baseline in HbA1c at Week 12

HbA1c is measured as percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent

Time frame: Baseline and Week 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.